Summit Global Investments Lowers Stock Position in Cencora, Inc. $COR

Summit Global Investments cut its stake in shares of Cencora, Inc. (NYSE:COR) by 27.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,130 shares of the company’s stock after selling 3,441 shares during the period. Summit Global Investments’ holdings in Cencora were worth $2,868,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. JFS Wealth Advisors LLC increased its holdings in Cencora by 30.2% in the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after purchasing an additional 29 shares during the last quarter. Apollon Wealth Management LLC raised its position in Cencora by 0.5% in the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after purchasing an additional 30 shares during the period. Accent Capital Management LLC lifted its stake in Cencora by 36.1% during the fourth quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock worth $38,000 after purchasing an additional 30 shares in the last quarter. MCF Advisors LLC lifted its stake in Cencora by 11.0% during the fourth quarter. MCF Advisors LLC now owns 303 shares of the company’s stock worth $102,000 after purchasing an additional 30 shares in the last quarter. Finally, CYBER HORNET ETFs LLC boosted its position in shares of Cencora by 6.8% during the fourth quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock worth $164,000 after buying an additional 31 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the transaction, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of a number of research reports. Robert W. Baird dropped their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Citigroup lowered their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Finally, Morgan Stanley set a $342.00 price target on shares of Cencora in a research report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Cencora Trading Down 1.4%

COR opened at $303.65 on Tuesday. The business has a fifty day moving average price of $280.85 and a 200 day moving average price of $317.26. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a market capitalization of $59.08 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 1.71 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the business posted $4.42 EPS. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has initiated a stock buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.